Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pulmonx Corp

7.52
+0.47006.67%
Post-market: 7.520.00000.00%18:25 EDT
Volume:192.85K
Turnover:1.43M
Market Cap:299.27M
PE:-5.22
High:7.53
Open:7.04
Low:7.04
Close:7.05
Loading ...

Company Profile

Company Name:
Pulmonx Corp
Exchange:
NASDAQ
Establishment Date:
1995
Employees:
291
Office Location:
700 Chesapeake Drive,Redwood City,California,United States
Zip Code:
94063
Fax:
- -
Introduction:
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

Directors

Name
Position
Glendon E. French
President, Chief Executive Officer and Director
Dana G. Mead, Jr.
Director and Chairperson of the Board
Daniel Florin
Director
Georgia Garinois Melenikiotou
Director
Richard Ferrari
Director
Staffan Lindstrand
Director
Thomas W. Burns
Director

Shareholders

Name
Position
Glendon E. French
President, Chief Executive Officer and Director
Derrick Sung
Chief Financial Officer
Geoffrey Beran Rose
Chief Commercial Officer